Integer's stock plummeted 5.02% intraday on Friday, following a negative analyst note from Citi.
Citi lowered its price target on Integer to $89 from $92 while maintaining a Neutral rating on the shares. This reduction in price target may have contributed to investor concerns and selling pressure.
Analysts have recently been offering insights on healthcare companies including Integer Holdings, but the specific downgrade from Citi appears to have driven the sharp decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.